| Objective To evaluate the effectineness and safety of intraperitoneal hyperthermic perfusion chemotherapy(IHPC) for ovrian cancer, so as to provide references for clinical practice and study.Methods The following datebases including the Embase, Cochrane Library, Web of Science, Pubmed, WangFang, CBM, VIP and CNKI were searched on computer, from the data of their estabishment to June 2013, relevant journals such as Chinses Journal of Obstetrics Gynecology, Chinses Journal of Practical Gynecology and Obstetrics and Archives of Gynecology and Obstetrics were handsearched, meanwhile we search for relevant literatures with Google and other search engines on the Internet. To collect all relevant randomized controlled trials (RCTs) on IHPC versus intravenous chemotherapy alone(IC)for ovarian cancer. After two researchers independently according to the Cochrane Handbook 5.0.1 quality evaluation standard to evaluate the inclusion literatures, and Meta-analysis was conducted by using RevMan 5.1 software.Rescults A total of 10 RCTs involving 723 patients were included. The results of meta-analyses showed that there were significant difrences between the IHPC group and IC group in clinical efficient, clinical benefit response, recurrence and metastasis rate, overall survival and ascities control rate; the OR value and 95%CI were 4.02 (2.85,5.68),3.14 (2.13,5.45), 029(0.20,0.42),3.30 (1.82,5.99) and 4.46(1.98,10.02) respectively; between the two groups there were no significant differences in bone marrow suppression, hemoglobin decreased, nausea and vomiting.Conclusion Compared with IC, IHPC+IC can improve clinical efficient, clinical benefit response and overall survival and reduce recurrence and metastasis rate; additionally, it is safe and feasible, so it is recommended that the specifical condition of patients should be taken into consideration when the therapy is applied to clinic. |
PDF Full Text Request